Takeda And Pfizer Sign A Co-Promotion Deal To Market Actos In China
This article was originally published in PharmAsia News
Executive Summary
Facing a looming patent cliff, Japan's Takeda made good on a pledge to dive into emerging markets by signing a co-promotion deal with Pfizer to market its type 2 Actos diabetes drug in China